An in vitro transcription assay for probing drug-DNA interactions at individual drug sites
Time of Update: 2020-11-21
An in vitro transcription assay of drug- DNA interactions has been described and is based largely on the stable lac UV5-initiated transcription complex.
New anti-inflammatory drugs! Bronger Ingeham terminates clinical development of AOC3 inhibitor BI1467335: there is a risk of drug interaction!
Time of Update: 2020-09-27
September 08, 2020 // -- Boehringer Ingelheim and Pharmaxis recently jointly announced the termination of the development of BI1467335 for the treatment of moderate to non-proliferative diabetic retinal lesions (NPDR).
The meeting previewed I "drug combustion" Kaidong - 2020 biopharmaceutical production and integration interactive forum.
Time of Update: 2020-09-05
Contractors: Kaidong High-tech Industrial Development Zone Management Committee, Wise Pharmaceutical Jiangsu Co., Ltd., Huaxing Capital Holdings Co., Ltd., Fahrenheit Kangyuan Pharmaceutical Technology Co., Ltd. Co-technology Media: Easy Enterprise
The interaction mechanism of the Robo receptor with the Wnt-Ror signaling pathway.
Time of Update: 2020-08-11
's research over the past few decades has found dozens of guided signal molecules that act on the growth cone surface receptors and control the targeted extension of nerve bursts by regulating the dynamic motion of the cytoskeleton.
New migraine drug! AbbVie oral CGRP receptor antagonist atogepant prevention migraine Phase III clinical success!
Time of Update: 2020-08-06
data showed that all atogepant dose groups reached the primary endpoint and that the average number of migraine days per month was statistically significantly reduced compared to placebos.
New anti-transplant drugs! IL-2 Receptor Targeting Immunotherapy Leukotac is on the market
Time of Update: 2020-07-31
application (BLA) for the treatment of patients with SR-aGvin disease in the class II-IV steroid refractive acute transplantation (SR-aGv). the BLA will be reviewed through the FDA Real-Time Oncology Review Pilot Program (RTOR), an initiative
PNAS: Receptor binding of SARS-CoV-2 is enhanced through hydrogen bond and hydrophobic interaction.
Time of Update: 2020-07-19
, June 28, 2020 // bio-valley BIOON/-- Severe Acute Respiratory Syndrome Type 2 coronavirus (SARS-CoV-2) enhanced receptor binding is thought to be the cause of the highly contagious transmission rate of coronavirus disease
A new drug for specific dermatitis (AD) itching! New anti-inflammatory drug: IL-31 receptor
Time of Update: 2020-07-17
the percentage of patients with a quality of life index (DLQI) score of 4, 40 percent in the nemolizumab group and 22 percent in the placebo group.
New drugs for insomnia! The eludant of ego receptor seroinion, Dayvigo (lemborexant), is on the market in Hong Kong, China!
Time of Update: 2020-07-14
, July 09, 2020 / bio-valley smh.com.au/Eisai has announced that a new drug application for its insomnia drug Dayvigo (lemborexant) has been accepted by the Hong Kong Special Administrative Region Of China Health Department
A new HIV-1 receptor may become a target for the development of new AIDS drugs
Time of Update: 2020-07-04
Integrator alpha4 beta7 is a normal component of human cells, located in the mucous membrane of the digestive tract, and is the peripheral T-cell nesting receptor.
EU approves type 2 diabetes drug GLP-1 receptor agonist Rybelsus
Time of Update: 2020-06-25
Novo Nordisk today announced that the European Medicines Agency (EMA) has approved the sale of the company's oral GLP-1 receptor agonisant Rybelsus (semaglutide) to help control blood sugar in people with type 2 diabetes.
New drugs for insomnia! The eludant of ego receptor serombia is available in the United States!
Time of Update: 2020-06-17
, June 04, 2020 / PRNewswire/ -- Eisai, a Japanese pharmaceutical company, recently announced the launch of the new insomnia drug Dayvigo (lerexmboant) CIV in the U.S. market, which comes in two sizes (5mg and 10mg tablets
FDA accepts new drug application from androgen receptor (AR) antagonist darolutamide
Time of Update: 2020-06-09
FDA ( accepted the company's application for new drug ( (NDA) for the androgen receptor (AR) antagonist darolutamide for the treatment of non-metastatic resistance prostate cancer (CRNM).
"Reducing damage and strengthening repair"! Besttime Squibb Multi-Astal Sclerosis New Drug: Oral
Time of Update: 2020-05-30
May 28, 2020 / Biovalley BIOON/ -- The European Commission (EC) has approved Zeposia (ozanimod) for the treatment of recurrent-remission-remission multiple sclerosis (RRMS) adult patients with active diseases (defined as clinical or imaging characteristics).
(Interactive) Botten shares: 108 workshop can produce innovative drug GMP intermediates
Time of Update: 2020-05-13
(Interactive) Botten shares : 108 workshop can produce new drugs GMP intermediates source: Panorama author: 2014-08-19 23:20:15 font: CICC Online Weibo WeChat plus
Systemic lupus erythematosus (SLE) new drug! AstraZeneca type I interferon receptor targeting mAb anifrolumab key phase III clinical success!
Time of Update: 2020-01-23
January 23, 2020 / BIOON / -- recently, the results of the tulip 2 study (nct02446899) on the key phase III of AstraZeneca in the treatment of systemic lupus erythematosus (SLE
, a new ADC drug, for the treatment of patients with folate receptor positive platinum resistance
Time of Update: 2019-12-30
December 30, 2019 / BIOON / -- immunogen is a clinical stage biotechnology company focusing on the development of a new generation of antibody drug conjugate (ADC) to improve
Treatment of chemotherapy-induced thrombocytopenia! Doplet, an oral thrombopoietin receptor agonist, has been approved as an orphan drug by FDA!
Time of Update: 2019-12-30
In the United States, doplet was approved by FDA in May 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who plan to undergo surgery.
New asthma drug! Two phase III clinical studies of fevipiprant (qaw039), a DP2 receptor antagonist of Novartis, failed!
Time of Update: 2019-12-17
December 17, 2019 / BIOON / -- Novartis recently released the latest results of the key global phase III study of the new asthma drug fevipiplant (qaw039) on luster-1 and luster-2.
Second progressive multiple sclerosis (SPMS) is the first oral drug! Mayzent, a new generation
Time of Update: 2019-11-18
November 18, 2019 / BIOON / - Novartis, a Swiss pharmaceutical giant Novartis recently announced that the European Drug Administration (EMA) Committee on human medicinal products